Day: May 10, 2024

FORT WORTH, Texas, May 10, 2024 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the first fiscal quarter of 2024. Highlights from First Quarter 2024: Revenues were $19.3 million, down 5.3% from 2023 Generated operating income of $0.7 million Net income of $0.5 million, down from $0.7 million in 2023 Gross margins of 56.7%, down from 58.1% in 2023 Operating expenses $10.3 million, down 5.2% from 2023 Adjusted EBITDA* of $1.1 million Ended quarter with $12.3 million of cash and cash equivalents Tandy Leather Factory’s first quarter sales were $19.3 million in 2024, down from $20.4 million in 2023. First quarter 2024 gross profit was $10.9 million, down from $11.8 million in 2023. First quarter operating income was $0.7 million, down from $1.0 million in 2023. As of...

Revenues of $91.7 million compared to $83.1 million in the prior year period Pretax income of $6.6 million Net income of $4.6 million, or $0.19 per diluted share New contract purchases of $346.3 million LAS VEGAS, NV, May 10, 2024 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.6 million, or $0.19 per diluted share, for its first quarter ended March 31, 2024. This compares to a net income of $13.8 million, or $0.54 per diluted share, in the first quarter of 2023. Revenues for the first quarter of 2024 were $91.7 million, an increase of $8.6 million, or 10.4%, compared to $83.1 million for the first quarter of 2023. Total operating expenses for the first quarter of 2024 were $85.2 million compared to $64.7 million for the 2023 period. Pretax income for...

Reports Net Income of $4.3 Million or $0.10 per Diluted Share, and Adjusted EBITDA of $7.1 Million CLAYTON, Mo., May 10, 2024 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the first quarter ended March 31, 2024. First quarter 2024 Financial Highlights (all comparisons are with the first quarter of 2023) Revenues were $58.3 million, a decrease of 21% or $15.9 million compared to $74.2 million. Net income was $4.3 million, or $0.10 per diluted share, down from $21.1 million, or $0.48 per diluted share. Adjusted EBITDA(1) was $7.1 million, down from $15.9 million. (1) A non-GAAP financial measure. See “Non-GAAP Financial Measures” for a description of the measure and a reconciliation to the applicable GAAP measure. “We...

HAUPPAUGE, N.Y., May 10, 2024 (GLOBE NEWSWIRE) — Forward Industries, Inc. (NASDAQ:FORD), a global design, sourcing and distribution group, today announced financial results for its second quarter ended March 31, 2024. Second Quarter Fiscal Year 2024 Financial Highlights    Revenues were $7.8 million, a decrease of 19.6% from $9.7 million for 2023. Gross margin increased to 20.5% compared to 19.8% for 2023. Loss from continuing operations was $0.5 million compared to $0.1 million in 2023 and net loss was $0.6 million compared to $0.9 million in 2023. Basic and diluted loss per share from continuing operations was $0.05 compared to $0.01 for 2023. Cash balance of $2.3 million at March 31, 2024 compared to $3.2 million at September 30, 2023. Terry Wise, Chief Executive Officer of Forward Industries, stated “The business continues...

JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. “Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatments for patients with GYN/endocrine, metabolic and gastrointestinal disorders. We thank our shareholders for their support. We are continuing on our mission to build Entera into a premier oral peptide therapeutic company and look forward to delivering key updates across all of our programs as this year progresses,” said Miranda...

ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) — Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter ended March 31, 2024. Revenues for the first quarter of 2024 totaled $47.3 million compared to $40.0 million for the same period in 2023. For the just ended quarter, operating income was $3.1 million, down $1.3 million from the comparable 2023 period, primarily due to a one-time inventory write-off, and net income was $2.8 million, down $0.7 million from the same period in 2023. First quarter 2024 diluted earnings per share were $1.59 compared to $1.98 for the first quarter of 2023. Commenting on the results for the first quarter of 2024 compared to the prior year period, David Battat, President and CEO, stated, “Revenues grew 18% and operating income was up 22%, excluding the one-time inventory write...

$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $45 million, driven primarily by expenses for our clinical program in Alzheimer’s disease. Current Updates on Phase 3 Clinical ProgramBackground...